Shu-Chih Chen - 12 May 2026 Form 4 Insider Report for ATOSSA THERAPEUTICS, INC. (ATOS)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
14 May 2026, 16:27:40 UTC
Prior SEC filing
16 May 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Shu-Chih Chen

Key filing fact

Shu-Chih Chen filed Form 4 for ATOSSA THERAPEUTICS, INC. (ATOS) on 14 May 2026.

Key facts

  • This page summarizes Shu-Chih Chen's Form 4 filing for ATOSSA THERAPEUTICS, INC. (ATOS).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 14 May 2026, 16:27.

Change

  • Previous filing in this sequence was filed on 16 May 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001552127 Primary reporting owner

Chen Shu-Chih

Relationship
Director
Address
C/O ATOSSA THERAPEUTICS, INC., 1448 NW MARKET STREET SUITE 500, SEATTLE
Signature
Shu-Chih Chen
Signature date
14 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATOS transaction

Common Stock

Award

Transaction value
Shares
+10,000
Change %
Price
$0.000000*
Shares after
10,000
Date
12 May 2026
Ownership
Direct
Footnotes
F1
ATOS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,483
Date
12 May 2026
Ownership
By Ensisheim Partners, LLC
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026.

Footnote F2

Ensisheim Partners, LLC ("Ensisheim") is wholly owned by the Reporting Person and Dr. Steven C. Quay. The Reporting Person and Dr. Quay share voting and investment power over the securities held by Ensisheim. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .